AAAAAA

   
Results: 1-9 |
Results: 9
Safety of granulocyte colony-stimulating factor in normal donors
Authors: Gutierrez-Delgado, F Bensinger, W
Citation: F. Gutierrez-delgado et W. Bensinger, Safety of granulocyte colony-stimulating factor in normal donors, CURR OPIN H, 8(3), 2001, pp. 155-160
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
Authors: Storek, J Dawson, MA Storer, B Stevens-Ayers, T Maloney, DG Marr, KA Witherspoon, RP Bensinger, W Flowers, MED Martin, P Storb, R Appelbaum, FR Boeckh, M
Citation: J. Storek et al., Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation, BLOOD, 97(11), 2001, pp. 3380-3389
NCCN Practice Guidelines for breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, CE Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS McCormick, B Nabell, LM Reed, EC Silver, SM Smith, ML Somlo, G Theriault, R Ward, JH Winer, EP Wolff, A
Citation: Rw. Carlson et al., NCCN Practice Guidelines for breast cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 33-49
A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma
Authors: Stiff, P Gingrich, R Luger, S Wyres, MR Brown, RA LeMaistre, CF Perry, J Schenkein, DP List, A Mason, JR Bensinger, W Wheeler, C Freter, C Parker, WRL Emmanouilides, C
Citation: P. Stiff et al., A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma, BONE MAR TR, 26(5), 2000, pp. 471-481
High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer
Authors: Gutierrez-Delgado, F Holmberg, LA Hooper, H Appelbaum, FR Livingston, RB Maziarz, RT Weiden, P Rivkin, S Montgomery, P Kawahara, K Bensinger, W
Citation: F. Gutierrez-delgado et al., High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer, BONE MAR TR, 26(1), 2000, pp. 51-59
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE (R) STn-KLH cancer vaccine
Authors: Holmberg, LA Oparin, DV Gooley, T Lilleby, K Bensinger, W Reddish, MA MacLean, GD Longenecker, BM Sandmaier, BM
Citation: La. Holmberg et al., Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE (R) STn-KLH cancer vaccine, BONE MAR TR, 25(12), 2000, pp. 1233-1241
Busulfan, melphalan, and thiotepa with or without total marrow irradiationwith hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors
Authors: Hawkins, D Barnett, T Bensinger, W Gooley, T Sanders, E
Citation: D. Hawkins et al., Busulfan, melphalan, and thiotepa with or without total marrow irradiationwith hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors, MED PED ONC, 34(5), 2000, pp. 328-337
Update: NCCN practice guidelines for the treatment of breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, C Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS Mccormick, B Nabell, LM Reed, EC Silver, SM Smith, MLP Somlo, G Theriault, RL Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
Authors: Holmberg, LA Boeckh, M Hooper, H Leisenring, W Rowley, S Heimfeld, S Press, O Maloney, DG McSweeney, P Corey, L Maziarz, RT Appelbaum, FR Bensinger, W
Citation: La. Holmberg et al., Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation, BLOOD, 94(12), 1999, pp. 4029-4035
Risultati: 1-9 |